Abstract:BACKGROUND:Recent genomic and bioinformatic technological advances have made it possible to dissect the immune response to personalized neoantigens encoded by tumor-specific mutations. However, timely and efficient identification of neoantigens is still one of the major obstacles to using personalized neoantigen-based cancer immunotherapy.METHODS:Two different pipelines of neoantigens identification were established in this study: (1) Clinical grade targeted sequencing was performed in patients with refractory solid tumor, and mutant peptides with high variant allele frequency and predicted high HLA-binding affinity were de novo synthesized. (2) An inventory-shared neoantigen peptide library of common solid tumors was constructed, and patients' hotspot mutations were matched to the neoantigen peptide library. The candidate neoepitopes were identified by recalling memory T-cell responses in vitro. Subsequently, neoantigen-loaded dendritic cell vaccines and neoantigen-reactive T cells were generated for personalized immunotherapy in six patients.RESULTS:Immunogenic neo-epitopes were recognized by autologous T cells in 3 of 4 patients who utilized the de novo synthesis mode and in 6 of 13 patients who performed shared neoantigen peptide library, respectively. A metastatic thymoma patient achieved a complete and durable response beyond 29 months after treatment. Immune-related partial response was observed in another patient with metastatic pancreatic cancer. The remaining four patients achieved the prolonged stabilization of disease with a median PFS of 8.6 months.CONCLUSIONS:The current study provided feasible pipelines for neoantigen identification. Implementing these strategies to individually tailor neoantigens could facilitate the neoantigen-based translational immunotherapy research.TRIAL REGSITRATION. ChiCTR.org ChiCTR-OIC-16010092, ChiCTR-OIC-17011275, ChiCTR-OIC-17011913; ClinicalTrials.gov NCT03171220.FUNDING:This work was funded by grants from the National Key Research and Development Program of China (Grant No. 2017YFC1308900), the National Major Projects for "Major New Drugs Innovation and Development" (Grant No.2018ZX09301048-003), the National Natural Science Foundation of China (Grant No. 81672367, 81572329, 81572601), and the Key Research and Development Program of Jiangsu Province (No. BE2017607).

The Screening, Identification, Design and Clinical Application of Tumor-Specific Neoantigens for TCR-T Cells

Recent advances of neoantigen in tumor therapy

Neoantigens: promising targets for cancer therapy

Tumor Neoantigens: from Basic Research to Clinical Applications

Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges

TSNAdb: A Database for Tumor-specific Neoantigens from Immunogenomics Data Analysis.

Neoantigens and Their Potential Applications in Tumor Immunotherapy (Review)

Progress in Neoantigen Targeted Cancer Immunotherapies

Neoantigen: A New Breakthrough in Tumor Immunotherapy

Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy response

Cancer neoantigens as potential targets for immunotherapy

Development and Clinical Applications of Therapeutic Cancer Vaccines with Individualized and Shared Neoantigens

Neoantigens in Precision Cancer Immunotherapy: from Identification to Clinical Applications

Toward in silico Identification of Tumor Neoantigens in Immunotherapy

Neoantigen Identification Strategies Enable Personalized Immunotherapy in Refractory Solid Tumors

Emerging Strategies in TCR-Engineered T Cells

Identifying and engineering TCR specificity against solid tumor neoantigens

Utilizing immunogenomic approaches to prioritize targetable neoantigens for personalized cancer immunotherapy

Neoantigen-targeted TCR-T cell therapy for solid tumors: How far from clinical application

The Role of Neoantigens in Cancer Immunotherapy

The Neoantigens Derived from Transposable Elements - A Hidden Treasure for Cancer Immunotherapy